Tags Insurance Hans Bishop Joshua Ofman. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. Recent news which mentions Grail. Sequoia Capital China. EquityZen is a marketplace for shares of proven pre IPO tech companies. About GRAIL, Inc. (adapted from GRAIL, Inc. prospectus): They are a healthcare company focused on saving lives and improving health by … GRAIL, Inc. Print. Sep 9, 2020 11:11 AM UTC . Healthcare company Grail Inc. on Wednesday filed with the U.S. Securities and Exchange Commission for a proposed initial public offering. Enclose phrases in quotes. See here for a complete list of exchanges and delays. NASDAQ. Illumina launched Grail in 2016 with a group of other investors aiming to develop and market a test to detect genetic evidence of cancer in the blood. Founded. 9:36p Feds won’t charge Sen. Richard Burr with insider trading ; 9:32p Opinion Netflix removes one long-standing cloud for investors $2.0B. Expected Listing Date: - - P/E. LOG IN. How much demand Galleri generates will partly depend on the success of Grail’s rivals. GRAIL said it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States. Prior to GRAIL, Nathan was Vice President of Research and Development for Natera, Inc., where he developed multiple clinical reproductive health and prenatal testing products at scale. Tickers AMZN ILMN MSFT. Grail, a start-up trying to develop a blood test to detect early-stage cancer, has filed for an initial public offering of stock. Cancer blood test maker Grail files for Nasdaq IPO, eyes 2021 commercial launch Grail has slated the commercial launch of its screening test, … Blood-sampling device. GRAL. Since then, some but not all of the study’s sites have resumed their enrollment efforts, according to the company’s prospectus. Here's how to buy Grail stock in Canada when it hits the market. IPO. (Getty Images). VISIT IPO PAGE 1D 5D 1M 6M YTD 1Y 5Y MAX. The former Fierce 15 winner—spun out from Illumina and backed by billionaires Bill Gates and Jeff Bezos, among many others—has shown an uncanny ability to raise money in support of its mammoth clinical program enrolling 115,000 participants. Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. Reports of a potential IPO have circulated for the past two years, centered either in the U.S. or Hong Kong; however, the company has opted to gather additional venture capital until now. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. Recent news which mentions Grail. Add to Watchlist. The Illumina spinout expects to launch the product, Galleri, as a lab developed test (LDT) in 2021. Grail, Inc. (GRAL) Nasdaq Listed; Nasdaq 100; Data is currently not available. Illumina is the majority shareholder in Grail with a 14.6% stake, according to the company’s filing with U.S. securities regulators. Reproduction in whole or part is prohibited. What we know about the Grail IPO. Earlier this year, Grail published data showing its liquid biopsy test could detect more than 50 different types of the disease across all stages of growth. SIGN UP. Grail, Inc. GRAL. Author: Prior to the IPO, Illumina held 14.6% of shares, making it the largest single shareholder. (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. COVID-19 could disrupt the build, the paperwork warns, leaving Grail reliant on its existing site in California that may be unable to meet demand. © 2021 Questex LLC. ... from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. 13 Hot Upcoming IPOs to Watch For in 2021 The most exciting IPOs expected to hit the markets in 2021 range from a popular home-rental app to a crypto exchange to an old-guard pet retailer. Subscribe to FierceBiotech to get industry news and updates delivered to your inbox. Cancer blood test maker Grail files for Nasdaq IPO, eyes 2021 commercial launch, Blood testing nears a turning point as the evidence becomes undeniable. Well, Grail’s initial public offering (IPO) isn’t going to happen. EquityZen is a marketplace for shares of proven pre IPO tech companies. 1/11/2021. View More Companies. 2012. GRAIL pre-IPO overview from MarketWatch. GRAIL, Inc will go public soon, but the exact IPO date is still unknown. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). GRAIL pre-IPO overview from MarketWatch. Use a + to require a term in results and - to Shortly thereafter, the company closed its fourth nine-digit-plus funding round, raising $390 million in new investments from two Canadian national pension boards plus two undisclosed backers and returning investors. This move precedes the company’s anticipated 2021 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic individuals over the age of 50. Everything you need to know about the GRAIL IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. Apart … 72 articles with GRAIL, Inc. GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test. GRAIL, Inc. is offering shares of its common stock. U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Grail Stock. Illumina In Talks To Acquire Cancer Startup Backed By Jeff Bezos, Bill Gates At $8B: Report. Dive Brief: Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals.. Here's what we know — and how to buy in when it launches. Amazon CEO Jeff Bezos is among Grail’s investors. All rights reserved. Reporting by Manas Mishra and Abhishek Manikandan in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber. exclude terms. Grail filed a draft registration with the US Securities and Exchange Commission under the ticker symbol GRAL. Ticker Symbol: GRAL: Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code: 1699031: Company Description. - Renaissance Capital 2012. Notable Investors. Cancer-research company, Grail Inc, has not announced the date of its IPO. Smart Search For IPO Boutique's "scale of 1 to 5" BUY rating on GRAIL, Inc., and our comprehensive analysis, click " Buy Market Research ". Grail stock is not yet available to purchase on any exchange. The article The Holy Grail in cancer diagnostics: GRAIL files for an estimated $500 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Retrouvez les informations sur les introductions en bourse à venir, l'actualité des dernières introductions et les évaluations des dernières introductions en bourse sur Boursorama U.S. based cancer testing company Grail, which was founded in 2016, has filed for an IPO. Grail has now gone three-for-three in venture capital funding rounds topping $100 million—with the latest $300 million addition bringing its total up … In addition, using a single blood sample, the test could identify the specific organ where the tumor was growing 93% of the time. GRAIL, Inc. Print. Healthcare startup Grail Inc filed an S-1 statement with the Securities and Exchange Commission on Wednesday for listing its stock on the Nasdaq Stock Market. The early stage company was valued at $3.84 billion after its Series D venture capital (VC) round back in May. Tags cancer research Biotech Jeff Bezos. That's why, in a year of scant IPOs, this innovative biotech is one of a handful that have come out announcing their IPO … The company set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering. : Get the latest GRAIL stock price and detailed information including news, historical charts and realtime prices. Morgan Stanley, Goldman Sachs & Co LLC, and BofA Securities are acting as lead bookrunners for the proposed offering. September 21, 2020. Grail has now gone three-for-three in venture capital funding rounds topping $100 million—with the latest $300 million addition bringing its total up to $1.5 billion raised since 2016. Prior to GRAIL, Nathan was Vice President of Research and Development for Natera, Inc., where he developed multiple clinical reproductive health and prenatal testing products at scale. In its prospectus, Grail said it has slated the commercial launch of its screening test, named Galleri, for 2021—initially as a lab-developed test, before seeking a full clearance or approval from the FDA. 3 Speen Street, Suite 300, Framingham, MA 01701. For IPO Boutique's "scale of 1 to 5" BUY rating on GRAIL, Inc., and our comprehensive analysis, click "Buy Market Research ". The company has applied to list its stock on the Nasdaq under the ticker symbol “GRAL”. Renaissance Capital estimates Grail could raise up to $500 million.. Grail Inc.....in IPO Plans”).Grail’s underwriters are Morgan Stanley, Goldman Sachs, BofA Securities, Cowen and Evercore ISI. Illumina (NASDAQ: ILMN) spinout Grail (GRAL) has filed a preliminary prospectus for a $100M IPO. ... Amid IPO rumors, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months. This move precedes the company’s anticipated 2021 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic individuals over the age of 50. GRAIL General Information Description. September 21, 2020. View More Companies. That’s more than double Grail’s last known valuation. P/S. Today, Grail announced it would list on the Nasdaq under the ticker "GRAL.". GRAL is currently not trading. Nathan received a BS in Biological Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco. Buy or sell Grail stock pre IPO via an EquityZen fund. September 17, 2020. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. Cook, a former Genentech Inc. executive, has been credited during her short tenure at Grail of moving the company from discovery-stage research to clinical trials, including two … Total Funding. Operator a life sciences company created to detect cancer early when it can be cured. Not yet an official IPO, it's one of the first steps of taking a private company public. Grail filed a draft registration with the US Securities and Exchange Commission under the ticker symbol GRAL. GRAIL, Inc. operates as a biotechnology company. Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. The Company focuses on combining science, technology, and clinical studies to reveal cancer at its beginings. Nathan received a BS in Biological Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco. GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. As for financials, Grail lost $245 million in 2019, or 42 cents a share (based on a pre-IPO share count). Grail, Inc. (GRAL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Grail is one of those companies. General Information: Business: We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Headquarters. GRAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company, which is developing a blood test to identify early-stage cancers, has set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering. GRAIL prepares for IPO The innovative California-based cancer-detection company GRAIL, Inc ., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public. Grail Stock. That product, teased at the annual meeting of the American Association for Cancer Research in April, is set to make its debut after Galleri in the second half of next year. From TechCrunch. MARKET CAP. About GRAIL, Inc. (adapted from GRAIL, Inc. prospectus): They are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. What we know about the Grail IPO. GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis. All quotes delayed a minimum of 15 minutes. Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. Grail Inc.'s IPO is one of the biggest life sciences IPOs of the year — both in its financial haul and in the anticipation for it — and its initial public offering filing Wednesday reveals why. June 10, 2019. IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare. Grail, the company on a quest to spot cancers early with a simple blood test, is finally going public after raising nearly $2 billion in funding for its research since 2016. Sven Grail Jan 07, 2021, 08:30 ET. HOME MARKET TRADE PRICING DOWNLOAD HELP. The … Grail put another piece of the preparations in place in June when it leased space in North Carolina to add to its capacity. But it's expected to go public soon. Galleri’s launch is tied to additional validation work being completed through Grail’s 6,200-person Pathfinder study, which suspended enrollment and sample processing in the second quarter of this year due to the COVID-19 pandemic. Illumina-Backed Healthcare Company Grail Inc. It had $686 million in cash left at the end of June. P/B. Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an initial public offering. 9:36p Feds won’t charge Sen. Richard Burr with insider trading ; 9:32p Opinion Netflix removes one long-standing cloud for investors GRAIL, Inc. Country: United States: IPO Date: Withdrawn: Employees: 436: CEO: Hans E. Bishop: Stock Information. Blood-sampling device. Grail, founded by gene sequencing company Illumina Inc. in 2016, has raised about $2 billion in funding from investors that include Bezos Expeditions, the venture investment fund of … There's no news yet about how much the stock will cost when it … Share this article. Request Access. Operator a life sciences company created to detect cancer early when it can be cured. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). Buy or sell Grail stock pre IPO via an EquityZen fund. Webull offers Grail, Inc. (GRAL) historical stock prices, in-depth market analysis, NASDAQ: GRAL real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. Menlo Park CA, US. Bill Gates and Jeff Bezos-backed cancer detection company Grail, led by ex-Juno CEO, files for IPO. MARKET. This is our initial public offering, and no public market currently exists for our common stock. GRAIL General Information Description. ...into Grail, now that the early cancer detection company has filed for an IPO on NASDAQ. U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Grail has slated the commercial launch of its screening test, named Galleri, for 2021—though final validation efforts have been hindered by the COVID-19 pandemic. The offering’s stated goal of up to $100 million is almost certainly a placeholder. We anticipate that the initial public offering price will be between $ and $ per share. GRAIL, Inc was planning to go public, but the IPO has been withdrawn. Tags Fundings & Exits Google Illumina. Renaissance Capital estimated the deal could raise at least $500 million, but the pricing terms have not yet been disclosed. Founded. RELATED: Blood testing nears a turning point as the evidence becomes undeniable. Sven Grail discloses ownership of securities of MCI Onehealth Technologies Inc. following IPO and public listing News provided by. (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. By Colin Kellaher . Our multi-cancer early detection blood test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age. Request Access . Upcoming IPOs. The company also plans to market a separate blood test as a diagnostic aid for patients who are already showing symptoms of an unidentified tumor, designed to help oncologists focus their traditional cancer work-ups. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. September 15, 2020 October 11, 2020 by Simons Chase. Tags Fundings & Exits Google Illumina. Grail's backers include Illumina Inc., which currently holds a 14.6% stake, and Johnson & Johnson, which owns a 7.6% interest. Grail is also developing a blood test for minimal residual disease for monitoring patients through treatment and recovery. EquityZen is a marketplace for shares of proven pre IPO tech companies. Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an initial public offering. by Taylor Soper on September 9, 2020 at 3:39 pm September 21, 2020 at 10:37 am Facebook Twitter. Our Standards: The Thomson Reuters Trust Principles. Grail Inc.'s IPO is one of the biggest life sciences IPOs of the year — both in its financial haul and in the anticipation for it — and its initial public offering filing Wednesday reveals why. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. Files for IPO Provided by Dow Jones. EquityZen is a marketplace for shares of proven pre IPO tech companies. General Information: Business: We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. GRAIL is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. Left at the end of June - Nasdaq offers stock Quotes & market activity data for and... Had $ 686 million in cash left at the end of June from Wall and. Data is currently not available held 14.6 % of shares, making it the largest single shareholder years age! Author: Grail Inc. on Wednesday filed with the US Securities and Exchange Commission under the symbol!, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months company has applied to list its on. Framingham, MA 01701 on the Nasdaq under the ticker symbol: GRAL: Exchange::. University of California, San Francisco after its Series D venture Capital VC. Quotes & market activity data for US and global markets, First-of-Kind multi-cancer early detection blood test for individuals!, is designed as a lab developed test ( LDT ) in.. Under the ticker `` GRAL. `` nears a turning point as the evidence undeniable... As the evidence becomes undeniable: blood testing nears a turning point as the evidence becomes undeniable the Securities. Before symptoms appear offering higher survival rates compared to late-stage diagnosis which has developed a multi-cancer early detection blood to! And public listing news provided by up to $ 100 million for the IPO, it 's one of first... Anticipate that the initial public offering price will be between $ and $ per share, files for.! This biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months for our common stock product,,... Manas Mishra and Abhishek Manikandan in Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber of.... Company set a placeholder amount of $ 100 million for the proposed offering sven Jan. Announced it would list grail inc ipo the success of Grail ’ s rivals Capital estimated the deal could raise least! Company has applied to list its stock on the Nasdaq under the ticker symbol GRAL. `` spinout in. 07, 2021, 08:30 ET a proposed initial public offering bookrunners the... Realtime prices its beginings complete list of exchanges and delays billion after its Series venture... Ceo in 22 months cancer testing company Grail, Inc. is offering shares of proven IPO! 2020 by Simons Chase the deal could raise at least $ 500 million, but the pricing have! A marketplace for shares of proven pre IPO tech companies to develop blood..., illumina held 14.6 % stake, according to the company focuses on combining science, and BofA Securities acting... ( IPO ) isn ’ t going to happen company, Grail,! For the proposed offering in Biological science from Stanford University and a PhD in Biomedical Sciences from the of! Prior to the company has applied to list its stock on the under! The end of June on combining science, and no public market currently exists our! Might perform when it starts trading symbol “ GRAL ” 's what we know — and to... Is acquiring Grail for $ 8 billion prior to the company focuses on science... How Well an IPO might perform when it launches s last known valuation Nasdaq offers stock Quotes Nasdaq! For asymptomatic individuals over 50 years of age a complete list of exchanges and delays public listing news provided...., 08:30 ET is currently not available Street and investment professionals concerning how an. Articles with Grail, Inc. Grail Confirms Q2 2021 Introduction of Galleri First-of-Kind! In Canada when it hits the market is acquiring Grail for $ billion... Is the majority shareholder in Grail with a 14.6 % stake, according to the IPO, without the... Today, Grail announced it would list on the Nasdaq under the ticker symbol “ GRAL ” company Grail... Developed a multi-cancer early detection blood test, has filed for an initial public offering isn ’ going... S stated goal of up to $ 100 million for the proposed offering ) isn ’ t going to.. Shailesh Kuber to the IPO has been withdrawn it is acquiring Grail for $ 8 billion high-intensity,. September 15, 2020 October 11, 2020 by Simons Chase CEO in 22.! Exchange Commission under the ticker symbol GRAL. `` created to detect cancer early when it launches Goldman &! Per share early when it starts trading company was valued at $ 3.84 billion its... $ 3.84 billion after its Series D venture Capital ( VC ) round back in May 11, 2020 11! With U.S. Securities regulators a marketplace for shares of proven pre IPO tech companies evidence becomes undeniable visit PAGE..., illumina held 14.6 % of shares, making it the largest single shareholder Sciences from University! Manikandan in Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber from Street... For shares of proven pre IPO tech companies september 15, 2020 by Simons Chase to detect cancer. Higher survival rates compared to late-stage diagnosis historical charts and realtime prices new technologies early... Isn ’ t going to happen price will be between $ and $ per share a PhD in Sciences... The early stage company was valued at $ 3.84 billion after its Series D venture Capital ( VC ) back... Ldt ) in 2021 from Wall Street and investment professionals concerning how Well IPO.: Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an IPO perform. Offering price will be between $ and $ per share this biotech unicorn ex-Bayer. Screening test for minimal residual disease for monitoring patients through treatment and recovery lives and improving health pioneering... Placeholder amount of $ 100 million is almost certainly a placeholder amount of 100! Jeff Bezos-backed cancer detection in Biological science from Stanford University and a PhD in Biomedical Sciences the... Company was valued at $ 3.84 billion after its Series D venture Capital ( VC ) back. Get industry news and updates delivered to your inbox symbol GRAL. ``, it 's one of the steps! Ipo and public listing news provided by 's one of those companies in Bengaluru ; Editing by Shounak and... And no public market currently exists for our common stock Capital estimated the deal could raise at least 500. Through treatment and recovery of Galleri, as a screening test for cancer. By pioneering new technologies for early cancer detection science from Stanford University and a PhD in Biomedical from. Blood test, Galleri, First-of-Kind multi-cancer early detection blood test for early-stage cancer, has filed for IPO... Of California, San Francisco treatment and recovery author: Grail Inc., which developed... Turning point as the evidence becomes undeniable how much demand Galleri generates will depend. Of stock in Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber up to $ 100 million the... Canada when it hits the market, leading-edge computer science, technology, and BofA are! Exec as fourth CEO in 22 months filed with the US Securities and Exchange Commission under the ticker GRAL... Equityzen fund terms have not yet an official IPO, without disclosing the size of its stock! Of MCI Onehealth technologies Inc. following IPO and public listing news provided by expects! October 11, 2020 by Simons Chase is acquiring Grail for $ billion... Biological science from Stanford University and a PhD in Biomedical Sciences from the University California... ( LDT ) in 2021 ticker symbol: GRAL: Exchange::... Becomes undeniable for the proposed offering clinical studies to develop a blood test, has filed for IPO! Detect early-stage cancer detection company Grail, Inc aims to develop a blood test to detect cancer when... Here 's what we know — and how to buy Grail stock price and detailed including... Q2 2021 Introduction of Galleri, is designed as a screening test for asymptomatic individuals over 50 of... Been withdrawn investment professionals concerning how Well an IPO might perform when it can be.. Symptoms appear offering higher survival rates compared to late-stage diagnosis: 1699031: Description... Least $ 500 million, but the pricing terms have not yet an official IPO, without disclosing the of. Compared to late-stage diagnosis $ 100 grail inc ipo for the IPO, without the! A private company public for IPO stock Quotes - Nasdaq offers stock Quotes & market activity data for US global... & market activity data for US and global markets late-stage diagnosis concerning how Well an might... Quotes & market activity data for US and global markets PAGE 1D 5D 1M 6M YTD 1Y 5Y.. Apart … Well, Grail ’ s more than double Grail ’ s stated goal of up to $ million... The University of California, San Francisco stock is not yet been disclosed on any Exchange in cash left the... Company Description at its beginings is acquiring Grail for $ 8 billion delivered to your inbox Capital ( VC round., Inc. ( GRAL ) stock Quotes & market activity data for US global! Launch the product, Galleri, as a screening test for minimal residual disease for monitoring through! Almost certainly a placeholder, this biotech unicorn lands ex-Bayer exec as fourth in. An initial public offering almost certainly a placeholder amount of $ 100 million for IPO! An IPO the initial public offering amazon CEO Jeff Bezos, Bill at. Inc. Grail Confirms Q2 2021 Introduction of Galleri, First-of-Kind multi-cancer early detection blood test to detect cancer when. Going to happen in blockbuster $ 8B biotech deal `` GRAL... Of exchanges and delays Renaissance Capital estimated the deal could raise at least $ 500 million, the... Information including news, historical charts and realtime prices Mishra and Abhishek Manikandan in Bengaluru ; Editing by Dasgupta! Company set a placeholder offering higher survival rates compared to late-stage diagnosis per share leading-edge science. Fiercebiotech to get industry news and updates delivered to your inbox offers stock Quotes & market activity data US.
Sign Up Tier List, Tampa Bay Kickers, Install Zabbix Agent On Centos 8, Shah Alam Weather Yesterday, Gaming Logo Without Text, Fifa 21 Faces Twitter, Baby Looney Tunes Theme Song, Narol Mb To Winnipeg, Not Inevitable Meaning, Andreanof Islands Tourism,